G-NiiB Immunity Formula (SIM01)

Long COVID refers to the long-term symptoms that persist after acute COVID-19, with no effective treatment. CUHK conducted the world’s first large-scale, double-blind, randomised, placebo-controlled trial (RECOVERY) to confirm that treatment with an oral synbiotic preparation (SIM01) could lead to significant alleviation in various symptoms of post-acute COVID-19 syndrome (PACS).

• Scientifically formulated using CUHK’s proprietary faecal metagenomics and clinical data, targeting specific microbiome dysbiosis observed in COVID-19 and Long COVID patients.
• Unique blend of 3 Bifidobacterium species and 3 prebiotics, to improve gut dysbiosis specifically linked to Long COVID pathogenesis.
• First oral microbiome formula with RCT evidence demonstrating significant Long COVID symptom reduction.

• Clinical assessments confirmed that the SIM01 group had significantly higher alleviation rates in five PACS symptoms, including fatigue, difficulty in concentration, memory loss, gastrointestinal upset and general unwellness, than the placebo group.
• Treatment with SIM01 significantly enhanced the diversity and richness of gut microbiota, promoted the growth of multiple beneficial bacteria, and inhibited potentially pathogenic bacteria, thereby maintaining microbial balance.
• SIM01 increased 30 beneficial bacteria (including SCFA-producing bacteria), hence improved the functions of gut microbiota by promoting the production and release of short-chain fatty acids (SCFAs).
• These RCT findings have been published in The Lancet Infectious Diseases, the world-leading journal in infectious diseases, offering important directions for the treatment of Long COVID globally.

• Silicon Valley International Inventions Festival 2024 - Gold Medal
• Silicon Valley International Inventions Festival 2024 - Prize of the International Federation of Inventors’ Association (IFIA)
• 47th International Exhibition of Inventions Geneva - Gold Medal
• 49th International Exhibition of Inventions Geneva - Gold Medal
• NutraIngredients Awards Asia 2022 - Product of the Year: Probiotic
• NielsenIQ BASES Top Breakthrough Innovation Award 2022

• Alleviates multi-system symptoms by restoring gut microbiome balance after acute COVID-19.
• Enhances the diversity and richness of gut microbiota, promotes the growth of multiple beneficial bacteria, and inhibits potentially pathogenic bacteria.
• Increases 30 beneficial bacteria (including SCFA-producing bacteria), to improve the functions of gut microbiota by promoting the production and release of short-chain fatty acids (SCFAs).